Skip to main content
Top
Published in: BMC Immunology 1/2015

Open Access 01-12-2015 | Review

What is infectiveness and how is it involved in infection and immunity?

Authors: Liise-anne Pirofski, Arturo Casadevall

Published in: BMC Immunology | Issue 1/2015

Login to get access

Abstract

Proof of the Germ theory of disease and acceptance of Koch’s postulates in the late 1890’s launched the fields of microbial pathogenesis and infectious diseases and provided the conceptual framework that has guided thought and research in these fields. A central tenet that emerged from studies with microbes that fulfilled Koch’s postulates was that microbes that caused disease had characteristics that allowed them to do so, with the corollary that microbes that did not cause disease lacked disease-causing determinants. This observation, which held true for many diseases that were known to cause disease in the late 19th century, such as toxin-producing and encapsulated bacteria, led to the view that the ability to cause disease rested with microbes and reflected the activity of specific determinants, or virulence factors. With the dawn of the 20th century, efforts to neutralize virulence factors were under development and ultimately translated into anti-microbial therapy in the form of antibodies targeted to toxins and polysaccharide capsules. However, the 20th century progressed, antibiotics were identified and developed as therapy for infectious diseases while other medical advances, such as specialized surgeries, intensive care units, intravenous catheters, and cytotoxic chemotherapy became commonplace in resourced nations. An unintended consequence of many of these advances was that they resulted in immune impairment. Similarly, HIV/AIDS, which emerged in the late 1970’s also produced profound immune impairment. Unexpectedly, the prevailing view that microbes were the sole perpetrators of virulence was untenable. Microbes that were rarely if ever associated with disease emerged as major causes of disease in people with impaired immunity. This phenomenon revealed that available explanations for microbial infectiveness and virulence were flawed. In this review, we discuss the question ‘what is infectiveness’ based on the tenets of the Damage-response framework.
Literature
1.
go back to reference Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150–61.CrossRefPubMed Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150–61.CrossRefPubMed
2.
go back to reference Casadevall A, Pirofski L. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect Immun. 1999;67:3703–13.PubMedCentralPubMed Casadevall A, Pirofski L. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect Immun. 1999;67:3703–13.PubMedCentralPubMed
3.
go back to reference Casadevall A, Pirofski L. Host-pathogen interactions. II. The basic concepts of microbial commensalism, colonization, infection and disease. Infect Immun. 2000;68:6511–8.CrossRefPubMedCentralPubMed Casadevall A, Pirofski L. Host-pathogen interactions. II. The basic concepts of microbial commensalism, colonization, infection and disease. Infect Immun. 2000;68:6511–8.CrossRefPubMedCentralPubMed
4.
go back to reference Casadevall A, Pirofski L. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol. 2003;1:17–24.CrossRefPubMed Casadevall A, Pirofski L. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol. 2003;1:17–24.CrossRefPubMed
5.
go back to reference Casadevall A, Pirofski L. Host-pathogen interactions: the attributes of virulence. J Infect Dis. 2001;184:337–45.CrossRefPubMed Casadevall A, Pirofski L. Host-pathogen interactions: the attributes of virulence. J Infect Dis. 2001;184:337–45.CrossRefPubMed
6.
go back to reference Casadevall A, Pirofski L. What is a host? Incorporating the microbiota into the damage-response framework. Infect Immun. 2014.In press. Casadevall A, Pirofski L. What is a host? Incorporating the microbiota into the damage-response framework. Infect Immun. 2014.In press.
7.
go back to reference Linden PK. History of solid organ transplantation and organ donation. Crit Care Clin. 2009;25(1):165–84. 1.CrossRefPubMed Linden PK. History of solid organ transplantation and organ donation. Crit Care Clin. 2009;25(1):165–84. 1.CrossRefPubMed
9.
go back to reference Casadevall A. Crisis in infectious diseases: time for a new paradigm? Clin Infect Dis. 1996;23:790–4.CrossRefPubMed Casadevall A. Crisis in infectious diseases: time for a new paradigm? Clin Infect Dis. 1996;23:790–4.CrossRefPubMed
11.
12.
13.
go back to reference Altizer S, Ostfeld RS, Johnson PT, Kutz S, Harvell CD. Climate change and infectious diseases: from evidence to a predictive framework. Science. 2013;341(6145):514–9.CrossRefPubMed Altizer S, Ostfeld RS, Johnson PT, Kutz S, Harvell CD. Climate change and infectious diseases: from evidence to a predictive framework. Science. 2013;341(6145):514–9.CrossRefPubMed
14.
go back to reference Altizer S, Bartel R, Han BA. Animal migration and infectious disease risk. Science. 2011;331(6015):296–302.CrossRefPubMed Altizer S, Bartel R, Han BA. Animal migration and infectious disease risk. Science. 2011;331(6015):296–302.CrossRefPubMed
15.
go back to reference Garcia-Solache MA, Casadevall A. Global warming will bring new fungal diseases for mammals. MBio. 2010;1(1). Garcia-Solache MA, Casadevall A. Global warming will bring new fungal diseases for mammals. MBio. 2010;1(1).
16.
go back to reference Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.CrossRefPubMed Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.CrossRefPubMed
17.
go back to reference Broz P, Monack DM. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol. 2013;13(8):551–65.CrossRefPubMed Broz P, Monack DM. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol. 2013;13(8):551–65.CrossRefPubMed
19.
go back to reference Netea MG, van de Veerdonk FL, van der Meer JW. Primary immunodeficiencies of pattern recognition receptors. J Intern Med. 2012;272(6):517–27.CrossRefPubMed Netea MG, van de Veerdonk FL, van der Meer JW. Primary immunodeficiencies of pattern recognition receptors. J Intern Med. 2012;272(6):517–27.CrossRefPubMed
20.
21.
go back to reference Picard C, Abel L, Casanova JL. Human monogenic disorders that confer predisposition to specific infections. Novartis Found Symp. 2007;281:65–73.CrossRefPubMed Picard C, Abel L, Casanova JL. Human monogenic disorders that confer predisposition to specific infections. Novartis Found Symp. 2007;281:65–73.CrossRefPubMed
22.
go back to reference Bassiri H, Janice Yeo WC, Rothman J, Koretzky GA, Nichols KE. X-linked Lymphoproliferative Disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses. Immunol Res. 2008;42(1–3):145–59.CrossRefPubMed Bassiri H, Janice Yeo WC, Rothman J, Koretzky GA, Nichols KE. X-linked Lymphoproliferative Disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses. Immunol Res. 2008;42(1–3):145–59.CrossRefPubMed
23.
go back to reference Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004;197:179–91.CrossRefPubMed Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004;197:179–91.CrossRefPubMed
24.
go back to reference Subramaniam K, Metzger B, Hanau LH, et al. IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J Infect Dis. 2009;200(2):244–51.CrossRefPubMedCentralPubMed Subramaniam K, Metzger B, Hanau LH, et al. IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J Infect Dis. 2009;200(2):244–51.CrossRefPubMedCentralPubMed
25.
go back to reference Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol. 2005;175(5):3262–7.CrossRefPubMed Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol. 2005;175(5):3262–7.CrossRefPubMed
26.
go back to reference Agematsu K, Futatani T, Hokibara S, et al. Absence of memory B cells in patients with common variable immunodeficiency. Clin Immunol. 2002;103(1):34–42.CrossRefPubMed Agematsu K, Futatani T, Hokibara S, et al. Absence of memory B cells in patients with common variable immunodeficiency. Clin Immunol. 2002;103(1):34–42.CrossRefPubMed
27.
go back to reference Kruetzmann S, Rosado MM, Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med. 2003;197(7):939–45.CrossRefPubMedCentralPubMed Kruetzmann S, Rosado MM, Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med. 2003;197(7):939–45.CrossRefPubMedCentralPubMed
28.
go back to reference Bernasconi NL, Taggiani E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2003;298:2199–202.CrossRef Bernasconi NL, Taggiani E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2003;298:2199–202.CrossRef
29.
go back to reference Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we need IgM memory B cells? Immunol Lett. 2013;152(2):114–20.CrossRefPubMed Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we need IgM memory B cells? Immunol Lett. 2013;152(2):114–20.CrossRefPubMed
30.
31.
Metadata
Title
What is infectiveness and how is it involved in infection and immunity?
Authors
Liise-anne Pirofski
Arturo Casadevall
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2015
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-015-0076-1

Other articles of this Issue 1/2015

BMC Immunology 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.